Nuplazid OverviewPimavanserin (ACP-103; BVF-036), sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being researched for the treatment of Alzheimer’s disease psychosis, schizophrenia, agitation, and major depressive disorder. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist. Contents 1 Pharmacology 1.1 Pharmacodynamics 2 History 2.1 De...
Read more Nuplazid Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pimavanserin
Recent Nuplazid Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 34mg
- Tablet: 10mg, 17mg
- Unknown: Unknown
NDC Database Records for Nuplazid: (3 results)Sorted by National Drug Code
- 63090-100 Nuplazid 10 mg Oral Tablet, Coated by Acadia Pharmaceuticals Inc
- 63090-170 Nuplazid 17 mg Oral Tablet, Coated by Acadia Pharmaceuticals Inc
- 63090-340 Nuplazid 34 mg Oral Capsule by Acadia Pharmaceuticals Inc